Korean pharmaceutical industry has potentiality in biotec.

Published: 2002-03-18 06:59:00

Updated: 2002-03-18 06:59:00

Mr. Robert A. Ingram, the CEO of Glaxo Smith Kline, who visited to Korea on March 11 took a press interview on 13, advising that the R&D of bio technology in the pharmaceutical industry should be closely bound with the business capacity. He added to say that the R&D for the new drug discovery too...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK